By comparing the effects of IL-33 deficiency (or exogenous administration) on orthotopic PDAC and heterotopic skin tumor growth, the authors demonstrated that TILC2 have tissue-specific effects on PDAC immunity that depended on IL-33/ST2. The gene discussed is IL33; the disease is skin neoplasm.